Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell mobilisation in lymphoproliferative diseases

N H Russell1, G McQuaker, C Stainer

  • 1Division of Haematology, School of Clinical Laboratory Sciences, University of Nottingham, UK.

Bone Marrow Transplantation
|December 16, 1998
PubMed
Summary

Optimizing peripheral blood stem cell (PBSC) collection for transplantation involves evolving regimens. Newer strategies, including G-CSF and combination therapies, offer improved efficacy and reduced toxicity compared to older methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

Clinical lymphoma, myeloma & leukemia·2021
Same author

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Leukemia·2018
Same author

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bone marrow transplantation·2017
Same author

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Leukemia·2017
Same author

Deficiencies in postgraduate training for healthcare professionals who provide diabetes education and support: results from the Diabetes Attitudes, Wishes and Needs (DAWN2) study.

Diabetic medicine : a journal of the British Diabetic Association·2017

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Peripheral blood stem cell (PBSC) mobilization is crucial for autologous transplantation in lymphoma and myeloma patients.
  • Early protocols relied on chemotherapy alone, but current methods utilize hematopoietic growth factors and cyclophosphamide.

Purpose of the Study:

  • To review and compare different regimens for PBSC mobilization.
  • To identify successful strategies for collecting optimal CD34+ cells with minimal toxicity and apheresis procedures.

Main Methods:

  • Review of existing literature on PBSC mobilization regimens.
  • Comparison of chemotherapy-alone, growth factor-based, and combination therapies.
  • Analysis of efficacy, toxicity, and patient factors influencing mobilization.

Related Experiment Videos

Main Results:

  • High-dose cyclophosphamide is effective but toxic; lower doses offer reduced toxicity with good efficacy.
  • 'Second-generation' salvage regimens show improved mobilization in lymphomas, reducing 'poor-mobilizers'.
  • Previous treatments (chemotherapy, radiotherapy) significantly impact PBSC mobilization success.

Conclusions:

  • Disease-specific mobilization strategies are emerging for lymphoma and myeloma.
  • G-CSF alone is a viable, non-toxic option for myeloma, with dosage being critical.
  • Further understanding of stem cell biology will refine future mobilization techniques.